Synthesis
of type I LacNAc (Galβ1 → 3GlcNAc) oligosaccharides
usually suffers from low yields. We herein report the efficient synthesis
of type I LacNAc oligosaccharides by chemoselective glycosylation.
With 16 relative reactivity values (RRVs) measured thiotoluenyl-linked
disaccharide donors and acceptors, chemoselective glycosylations were
investigated to obtain optimal conditions. In these reactions, the
RRV difference between the donors and acceptors had to be more than
6311 to obtain type I LacNAc tetrasaccharides in 72–86% yields,
with minimal occurrence of aglycon transfer. The threshold of RRV
difference was further applied to plan the synthesis of longer glycans.
Because it is challenging to measure the RRVs of tetrasaccharides,
anomeric proton chemical shifts were utilized to predict the corresponding
RRVs, which consequently explained the outcome of glycosylations for
the synthesis of type I LacNAc hexasaccharides. The result supported
the idea that elongation of glycan chains has to proceed from the
reducing to the nonreducing end for a better yield.
We recently developed a facile synthesis to yield orthogonally protected mannose‐ and Gal‐β1,3/4‐GlcNAc‐containing oligosaccharides. With optimized reaction conditions, the protection/glycosylation steps were carried out in a successive manner, without purification of intermediate products. The entire development sequence is herein described in detail, including each installation and removal of protecting groups, the optimization of glycosylation reactions, the successive operation of reaction steps, and further applications for glycan synthesis. We also discuss the unsolved problems and current challenges.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.